通產麗星(002243.SZ):子公司擬發行不超16億元公司債券
格隆匯5月28日丨通產麗星(002243.SZ)公佈,為滿足公司全資子公司力合科創集團有限公司(“力合科創”)生產經營及戰略發展的資金需求、降低融資成本,結合力合科創實際經營情況等因素,力合科創擬公開發行公司債券和註冊發行債務融資工具。
此次公開發行公司債券的發行規模合計不超過人民幣16億元(含16億元)。具體發行規模根據國家法律、法規及證券監管部門的有關規定,根據力合科創資金需求情況和發行時的市場情況,在上述範圍內確定。
募集資金扣除發行費用後可用於償還有息債務、補充營運資金、對外投資等一種或多種用途或其他用途,具體募集資金用途由力合科創根據實際資金需求情況確定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.